439 related articles for article (PubMed ID: 28816150)
1. Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases.
Williams NL; Wuthrick EJ; Kim H; Palmer JD; Garg S; Eldredge-Hindy H; Daskalakis C; Feeney KJ; Mastrangelo MJ; Kim LJ; Sato T; Kendra KL; Olencki T; Liebner DA; Farrell CJ; Evans JJ; Judy KD; Andrews DW; Dicker AP; Werner-Wasik M; Shi W
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):22-30. PubMed ID: 28816150
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
[TBL] [Abstract][Full Text] [Related]
3. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.
Caballero JA; Sneed PK; Lamborn KR; Ma L; Denduluri S; Nakamura JL; Barani IJ; McDermott MW
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):303-9. PubMed ID: 22079723
[TBL] [Abstract][Full Text] [Related]
5. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.
Anderson ES; Postow MA; Wolchok JD; Young RJ; Ballangrud Å; Chan TA; Yamada Y; Beal K
J Immunother Cancer; 2017 Oct; 5(1):76. PubMed ID: 29037215
[TBL] [Abstract][Full Text] [Related]
6. Whole Brain Radiotherapy Versus Stereotactic Radiosurgery in Poor-Prognosis Patients with One to 10 Brain Metastases: A Randomised Feasibility Study.
Raman S; Mou B; Hsu F; Valev B; Cheung A; Vallières I; Ma R; McKenzie M; Beaton L; Rackley T; Gondara L; Nichol A
Clin Oncol (R Coll Radiol); 2020 Jul; 32(7):442-451. PubMed ID: 32085923
[TBL] [Abstract][Full Text] [Related]
7. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.
Brown PD; Jaeckle K; Ballman KV; Farace E; Cerhan JH; Anderson SK; Carrero XW; Barker FG; Deming R; Burri SH; Ménard C; Chung C; Stieber VW; Pollock BE; Galanis E; Buckner JC; Asher AL
JAMA; 2016 Jul; 316(4):401-409. PubMed ID: 27458945
[TBL] [Abstract][Full Text] [Related]
8. Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects.
Diao K; Bian SX; Routman DM; Yu C; Kim PE; Wagle NA; Wong MK; Zada G; Chang EL
J Neurosurg; 2018 Dec; 129(6):1397-1406. PubMed ID: 29303446
[TBL] [Abstract][Full Text] [Related]
9. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
Sperduto PW; Wang M; Robins HI; Schell MC; Werner-Wasik M; Komaki R; Souhami L; Buyyounouski MK; Khuntia D; Demas W; Shah SA; Nedzi LA; Perry G; Suh JH; Mehta MP
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1312-8. PubMed ID: 23391814
[TBL] [Abstract][Full Text] [Related]
10. Use of Stereotactic Radiosurgery in Elderly and Very Elderly Patients With Brain Metastases to Limit Toxicity Associated With Whole Brain Radiation Therapy.
Chen L; Shen C; Redmond KJ; Page BR; Kummerlowe M; Mcnutt T; Bettegowda C; Rigamonti D; Lim M; Kleinberg L
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):939-947. PubMed ID: 28602418
[TBL] [Abstract][Full Text] [Related]
11. The strategy of repeat stereotactic radiosurgery without whole brain radiation treatment for new brain metastases: Outcomes and implications for follow-up monitoring.
Shen CJ; Rigamonti D; Redmond KJ; Kummerlowe MN; Lim M; Kleinberg LR
Pract Radiat Oncol; 2016; 6(6):409-416. PubMed ID: 27687187
[TBL] [Abstract][Full Text] [Related]
12. Multi-institutional Nomogram Predicting Survival Free From Salvage Whole Brain Radiation After Radiosurgery in Patients With Brain Metastases.
Gorovets D; Ayala-Peacock D; Tybor DJ; Rava P; Ebner D; Cielo D; Norén G; Wazer DE; Chan M; Hepel JT
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):246-253. PubMed ID: 28068233
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases.
Patel KR; Shoukat S; Oliver DE; Chowdhary M; Rizzo M; Lawson DH; Khosa F; Liu Y; Khan MK
Am J Clin Oncol; 2017 Oct; 40(5):444-450. PubMed ID: 26017484
[TBL] [Abstract][Full Text] [Related]
14. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.
Brown PD; Ballman KV; Cerhan JH; Anderson SK; Carrero XW; Whitton AC; Greenspoon J; Parney IF; Laack NNI; Ashman JB; Bahary JP; Hadjipanayis CG; Urbanic JJ; Barker FG; Farace E; Khuntia D; Giannini C; Buckner JC; Galanis E; Roberge D
Lancet Oncol; 2017 Aug; 18(8):1049-1060. PubMed ID: 28687377
[TBL] [Abstract][Full Text] [Related]
15. Whole brain radiotherapy versus stereotactic radiosurgery for 4-10 brain metastases: a phase III randomised multicentre trial.
Zindler JD; Bruynzeel AME; Eekers DBP; Hurkmans CW; Swinnen A; Lambin P
BMC Cancer; 2017 Jul; 17(1):500. PubMed ID: 28743240
[TBL] [Abstract][Full Text] [Related]
16. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.
Chang EL; Wefel JS; Hess KR; Allen PK; Lang FF; Kornguth DG; Arbuckle RB; Swint JM; Shiu AS; Maor MH; Meyers CA
Lancet Oncol; 2009 Nov; 10(11):1037-44. PubMed ID: 19801201
[TBL] [Abstract][Full Text] [Related]
17. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
[TBL] [Abstract][Full Text] [Related]
18. Biological implications of whole-brain radiotherapy versus stereotactic radiosurgery of multiple brain metastases.
Xue J; Kubicek GJ; Grimm J; LaCouture T; Chen Y; Goldman HW; Yorke E
J Neurosurg; 2014 Dec; 121 Suppl():60-8. PubMed ID: 25434938
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of gastrointestinal brain metastases treated with radiotherapy.
Sanghvi SM; Lischalk JW; Cai L; Collins S; Nair M; Collins B; Unger K
Radiat Oncol; 2017 Feb; 12(1):43. PubMed ID: 28245881
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis.
Ojerholm E; Lee JY; Thawani JP; Miller D; O'Rourke DM; Dorsey JF; Geiger GA; Nagda S; Kolker JD; Lustig RA; Alonso-Basanta M
J Neurosurg; 2014 Dec; 121 Suppl():75-83. PubMed ID: 25434940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
